{"generic":"Edoxaban","drugs":["Edoxaban","Savaysa"],"mono":{"0":{"id":"jymcs0","title":"Generic Names","mono":"Edoxaban"},"1":{"id":"jymcs1","title":"Dosing and Indications","sub":[{"id":"jymcs1b4","title":"Adult Dosing","mono":"<ul><li>Do not use for treatment of nonvalvular atrial fibrillation if CrCl is greater than 95 mL\/min because of an increased risk of ischemic stroke; assess CrCl prior to initiation of therapy.<\/li><li><b>Switching from warfarin (or other vitamin K antagonist):<\/b> Discontinue current anticoagulant and initiate edoxaban when INR is 2.5 or less.<\/li><li><b>Switching from oral anticoagulants other than warfarin or from low-molecular-weight heparin:<\/b> Discontinue current anticoagulant and initiate edoxaban at the time of the next scheduled dose of the discontinued medication.<\/li><li><b>Switching from unfractionated heparin:<\/b> Discontinue the infusion and initiate edoxaban 4 hours later.<\/li><li><b>Switching to warfarin:<\/b> Reduce dose by 50%, initiate warfarin, and continue edoxaban until stable INR of 2 or greater achieved; measure INR at least weekly and just prior to edoxaban dose; alternatively, may discontinue edoxaban and initiate parenteral anticoagulant and warfarin at the next scheduled edoxaban dose<\/li><li><b>Switching to anticoagulant other than warfarin:<\/b> Discontinue edoxaban and administer the new oral or parenteral anticoagulant at the next scheduled edoxaban dose.<\/li><li><b>Surgery:<\/b> Discontinue at least 24 hours prior to the procedure and restart once adequate hemostasis established; expect 1 to 2 hours for pharmacodynamic effect; if oral therapy is restricted, parenteral anticoagulant may be used until edoxaban can be initiated<\/li><li><b>Arthroplasty of knee, Total - Postoperative deep vein thrombosis; Prophylaxis:<\/b> 30 mg ORALLY once daily starting 6 to 24 hours after surgery and continuing for 11 to 14 days (study dose)<\/li><li><b>Atrial fibrillation, Nonvalvular - Cerebrovascular accident; Prophylaxis - Embolism; Prophylaxis:<\/b> 60 mg ORALLY once daily<\/li><li><b>Deep venous thrombosis:<\/b> 60 mg ORALLY once daily beginning 5 to 10 days after initiating therapy with a parenteral anticoagulant<\/li><li><b>Pulmonary embolism:<\/b> 60 mg ORALLY once daily beginning 5 to 10 days after initiating therapy with a parenteral anticoagulant<\/li><\/ul>"},{"id":"jymcs1b5","title":"Pediatric Dosing","mono":"Safety and efficacy not established "},{"id":"jymcs1b6","title":"Dose Adjustments","mono":"<ul><li><b>CrCl greater than 95 mL\/min in nonvalvular atrial fibrillation:<\/b> Do not use; increased risk of ischemic stroke<\/li><li><b>Renal impairment (CrCl 15 to 50 mL\/min):<\/b> 30 mg orally once daily<\/li><li><b>Renal impairment (CrCl less than 15 mL\/min):<\/b> Use not recommended<\/li><li><b>Hepatic impairment, moderate or severe (Child-Pugh B and C):<\/b> Use not recommended<\/li><li><b>Hepatic impairment, mild (Child-Pugh A):<\/b> No adjustment required<\/li><li><b>Body weight 60 kg or less in DVT or pulmonary embolism:<\/b> 30 mg orally once daily<\/li><li><b>Concomitant P-glycoprotein (P-gp) inhibitors in DVT or pulmonary embolism:<\/b> 30 mg orally once daily; P-gp inhibitors include quinidine, verapamil, azithromycin, clarithromycin, erythromycin, itraconazole, and ketoconazole; reinstate 60 mg once daily if P-gp inhibitor discontinued and no other indication for reduced dose exists<\/li><li><b>Concomitant P-glycoprotein (P-gp) inhibitors in nonvalvular atrial fibrillation:<\/b> No dose adjustment necessary<\/li><\/ul>"},{"id":"jymcs1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Atrial fibrillation, Nonvalvular - Cerebrovascular accident; Prophylaxis - Embolism; Prophylaxis<\/li><li>Deep venous thrombosis<\/li><li>Pulmonary embolism<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><br\/>Arthroplasty of knee, Total - Postoperative deep vein thrombosis; Prophylaxis<br\/>"}]},"2":{"id":"jymcs2","title":"Black Box Warning","mono":"<b>Oral (Tablet)<\/b><br\/>Edoxaban should not be used in patients with nonvalvular arterial fibrillation who have a CrCl greater than 95 mL\/min due to an increased risk of ischemic stroke. Premature discontinuation of oral anticoagulant therapy may increase the risk of ischemic events. If edoxaban is discontinued for reasons other than pathological bleeding or therapy completion, consider covering with an alternative anticoagulant. Epidural or spinal hematomas, possibly resulting in permanent paralysis, may occur with edoxaban use during neuraxial anesthesia or spinal puncture. Consider the risk of edoxaban use in patients undergoing spinal procedures.<br\/>"},"3":{"id":"jymcs3","title":"Contraindications\/Warnings","sub":[{"id":"jymcs3b9","title":"Contraindications","mono":"Active pathological bleeding <br\/>"},{"id":"jymcs3b10","title":"Precautions","mono":"<ul><li>Black Box Warning:<\/li><li>-- Do not use in patients with CrCl greater than 95 mL\/min due to reduced efficacy<\/li><li>-- Premature discontinuation may increase the risk of ischemic events; if discontinued for reasons other than pathological bleeding or therapy completion, consider covering with alternative anticoagulant<\/li><li>-- Use caution in patients receiving neuraxial anesthesia or undergoing spinal puncture as there is increased risk of spinal or epidural hematoma, which may cause permanent paralysis; monitoring recommended; do not remove indwelling epidural catheters sooner than 12 hours after the last dose and wait 2 hours after catheter removal before administering<\/li><li>Cardiovascular:<\/li><li>-- Mechanical heart valves or moderate to severe mitral stenosis; use not recommended<\/li><li>Hematologic:<\/li><li>-- Serious and potentially fatal bleeding may occur<\/li><li>Hepatic:<\/li><li>-- Moderate or severe hepatic impairment (Child-Pugh B or C); use not recommended<\/li><li>Renal:<\/li><li>-- Renal impairment (CrCl 15 to 50 mL\/min); dose adjustment necessary<\/li><li>-- Renal impairment (CrCl less than 15 mL\/min); use not recommended<\/li><li>Concomitant Use:<\/li><li>-- Long-term use with other anticoagulants; not recommended<\/li><li>-- P-glycoprotein inducers (eg, rifampin); avoid use<\/li><\/ul>"},{"id":"jymcs3b11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"jymcs3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"jymcs4","title":"Drug Interactions","sub":{"1":{"id":"jymcs4b14","title":"Major","mono":"<ul><li>Abciximab (theoretical)<\/li><li>Aceclofenac (established)<\/li><li>Acemetacin (established)<\/li><li>Acenocoumarol (theoretical)<\/li><li>Alteplase, Recombinant (theoretical)<\/li><li>Amtolmetin Guacil (established)<\/li><li>Anagrelide (theoretical)<\/li><li>Anistreplase (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Ardeparin (theoretical)<\/li><li>Argatroban (theoretical)<\/li><li>Aspirin (theoretical)<\/li><li>Bivalirudin (theoretical)<\/li><li>Bromfenac (established)<\/li><li>Bufexamac (established)<\/li><li>Carbamazepine (established)<\/li><li>Celecoxib (established)<\/li><li>Certoparin (theoretical)<\/li><li>Choline Salicylate (established)<\/li><li>Clonixin (established)<\/li><li>Clopidogrel (theoretical)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Dalteparin (theoretical)<\/li><li>Danaparoid (theoretical)<\/li><li>Desirudin (theoretical)<\/li><li>Dexibuprofen (established)<\/li><li>Dexketoprofen (established)<\/li><li>Diclofenac (established)<\/li><li>Diflunisal (established)<\/li><li>Dipyridamole (theoretical)<\/li><li>Dipyrone (established)<\/li><li>Enoxaparin (theoretical)<\/li><li>Eptifibatide (theoretical)<\/li><li>Etodolac (established)<\/li><li>Etofenamate (established)<\/li><li>Etoricoxib (established)<\/li><li>Felbinac (established)<\/li><li>Fenoprofen (established)<\/li><li>Fepradinol (established)<\/li><li>Feprazone (established)<\/li><li>Floctafenine (established)<\/li><li>Flufenamic Acid (established)<\/li><li>Flurbiprofen (established)<\/li><li>Fondaparinux (theoretical)<\/li><li>Fosphenytoin (established)<\/li><li>Heparin (theoretical)<\/li><li>Ibuprofen (established)<\/li><li>Ibuprofen Lysine (established)<\/li><li>Iloprost (theoretical)<\/li><li>Indomethacin (established)<\/li><li>Ketoprofen (established)<\/li><li>Ketorolac (established)<\/li><li>Lepirudin (theoretical)<\/li><li>Lornoxicam (established)<\/li><li>Loxoprofen (established)<\/li><li>Lumiracoxib (established)<\/li><li>Meclofenamate (established)<\/li><li>Mefenamic Acid (established)<\/li><li>Meloxicam (established)<\/li><li>Morniflumate (established)<\/li><li>Nabumetone (established)<\/li><li>Nadroparin (theoretical)<\/li><li>Naproxen (established)<\/li><li>Nepafenac (established)<\/li><li>Niflumic Acid (established)<\/li><li>Nimesulide (established)<\/li><li>Oxaprozin (established)<\/li><li>Oxyphenbutazone (established)<\/li><li>Parecoxib (established)<\/li><li>Parnaparin (theoretical)<\/li><li>Phenindione (theoretical)<\/li><li>Phenobarbital (established)<\/li><li>Phenprocoumon (theoretical)<\/li><li>Phenylbutazone (established)<\/li><li>Phenytoin (established)<\/li><li>Piketoprofen (established)<\/li><li>Piroxicam (established)<\/li><li>Prasugrel (theoretical)<\/li><li>Primidone (established)<\/li><li>Proglumetacin (established)<\/li><li>Propionic Acid (established)<\/li><li>Propyphenazone (established)<\/li><li>Proquazone (established)<\/li><li>Protein C (theoretical)<\/li><li>Reteplase, Recombinant (theoretical)<\/li><li>Reviparin (theoretical)<\/li><li>Rifampin (established)<\/li><li>Rivaroxaban (theoretical)<\/li><li>Rofecoxib (established)<\/li><li>Salicylic Acid (established)<\/li><li>Salsalate (established)<\/li><li>Sodium Salicylate (established)<\/li><li>St John's Wort (established)<\/li><li>Streptokinase (theoretical)<\/li><li>Sulfinpyrazone (theoretical)<\/li><li>Sulindac (established)<\/li><li>Tenecteplase (theoretical)<\/li><li>Tenoxicam (established)<\/li><li>Tiaprofenic Acid (established)<\/li><li>Ticlopidine (theoretical)<\/li><li>Tinzaparin (theoretical)<\/li><li>Tipranavir (established)<\/li><li>Tirofiban (theoretical)<\/li><li>Tolfenamic Acid (established)<\/li><li>Tolmetin (established)<\/li><li>Treprostinil (theoretical)<\/li><li>Urokinase (theoretical)<\/li><li>Valdecoxib (established)<\/li><li>Vorapaxar (theoretical)<\/li><li>Warfarin (theoretical)<\/li><\/ul>"}}},"5":{"id":"jymcs5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Rash (3.6% to 4.2%)<\/li><li><b>Hematologic:<\/b>Anemia (Nonvalvular atrial fibrillation, 9.6%; DVT or pulmonary embolism, 1.7%), Bleeding, Clinically Relevant, Nonmajor (Nonvalvular atrial fibrillation, 9.4%; DVT or pulmonary embolism, 7.2%)<\/li><li><b>Hepatic:<\/b>Liver function tests abnormal (Nonvalvular atrial fibrillation, 4.8%; DVT or pulmonary embolism, 7.8%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Bleeding, Major (Nonvalvular atrial fibrillation, 3.1%; DVT or pulmonary embolism, 1.4%)<\/li><li><b>Neurologic:<\/b>Hemorrhagic cerebral infarction (Nonvalvular atrial fibrillation, 0.3%), Intracranial hemorrhage (Nonvalvular atrial fibrillation, 0.5%; DVT or pulmonary embolism, 0.1%)<\/li><li><b>Respiratory:<\/b>Interstitial lung disease (Nonvalvular atrial fibrillation, 0.2%)<\/li><\/ul>"},"6":{"id":"jymcs6","title":"Drug Name Info","sub":{"0":{"id":"jymcs6b17","title":"US Trade Names","mono":"Savaysa<br\/>"},"2":{"id":"jymcs6b19","title":"Class","mono":"<ul><li>Anticoagulant<\/li><li>Factor Xa Inhibitor<\/li><\/ul>"},"3":{"id":"jymcs6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jymcs6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jymcs7","title":"Mechanism Of Action","mono":"Edoxaban, a selective inhibitor of factor Xa, reduces generation of thrombin and thrombus formation by inhibiting free factor Xa, prothrombinase activity, and thrombin-induced platelet aggregation.<br\/>"},"8":{"id":"jymcs8","title":"Pharmacokinetics","sub":[{"id":"jymcs8b23","title":"Absorption","mono":"<ul><li>Tmax, Oral: 1 to 2 hours<\/li><li>Bioavailability, Oral: 62%<\/li><li>Effect of food: No effect on systemic exposure<\/li><\/ul>"},{"id":"jymcs8b24","title":"Distribution","mono":"<ul><li>Protein binding: 55%<\/li><li>Vd: 107 L<\/li><\/ul>"},{"id":"jymcs8b25","title":"Metabolism","mono":"<ul><li>Hepatic: Minimal<\/li><li>M-4: Active<\/li><li>Substrate of P-glycoprotein<\/li><\/ul>"},{"id":"jymcs8b26","title":"Excretion","mono":"<ul><li>Bile: Less than 50%<\/li><li>Renal: 50%<\/li><li>Renal clearance: 11 L\/hr<\/li><li>Dialyzable: No (hemodialysis), less than 7%<\/li><li>Total body clearance: 22 L\/hr<\/li><\/ul>"},{"id":"jymcs8b27","title":"Elimination Half Life","mono":"10 to 14 hours <br\/>"}]},"9":{"id":"jymcs9","title":"Administration","mono":"<b>Oral<\/b><br\/>May be taken with or without food <br\/>"},"10":{"id":"jymcs10","title":"Monitoring","mono":"<ul><li>Reduced signs and symptoms of DVT or pulmonary embolism indicates efficacy.<\/li><li>CrCl; before therapy initiation for nonvalvular atrial fibrillation indication<\/li><li>Anti-Xa activity; reliable for assessing below and on-therapy drug levels, but not for excess drug levels; normal prothrombin time may rule out excess drug levels<\/li><li>Signs or symptoms of neurological impairment; frequently in patients receiving epidural\/spinal anesthesia or puncture<\/li><\/ul>"},"11":{"id":"jymcs11","title":"How Supplied","mono":"<b>Savaysa<\/b><br\/>Oral Tablet: 15 MG, 30 MG, 60 MG<br\/>"},"13":{"id":"jymcs13","title":"Clinical Teaching","mono":"<ul><li>Warn patient to immediately report unusual bleeding or bruising.<\/li><li>Side effects may include rash.<\/li><li>Advise patient against sudden discontinuation, as stroke risk may increase.<\/li><li>Counsel patient to avoid aspirin and NSAIDs with drug.<\/li><li>Instruct patient to take a missed dose as soon as possible on the same day, then resume normal schedule.<\/li><\/ul>"}}}